Acquired Company
ARCA biopharma completed its merger with Oruka Therapeutics on 9/3/2024, and the combined company began trading on Nasdaq under the ticker ORKA.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California. Show more
855 Oak Grove Avenue, Menlo Park, CA, 94025, United States
Start AI Chat
Market Cap
1.613B
52 Wk Range
$5.49 - $36.51
Previous Close
$33.32
Open
$33.49
Volume
432,875
Day Range
$33.49 - $36.29
Enterprise Value
604.9M
Cash
349.2M
Avg Qtr Burn
-21.6M
Insider Ownership
3.57%
Institutional Own.
-
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
ORKA-001 (IL-23p19 Antibody) Details Psoriasis | Phase 2b Data readout | |
ORKA-002 (IL-17A/F Antibody) Details Hidradenitis Suppurativa (HS) | Phase 2 Initiation | |
ORKA-002 (IL-17A/F Antibody) Details Psoriasis | Phase 2 Initiation | |
ORKA-002 Details Psoriasis | Phase 2 Initiation | |
ORKA-001 Details Psoriasis | Phase 2a Data readout |
